Study to test the safety and efficacy of PF-04449913 with azacitidine versus placebo with azacitidine in patients with Intermediate-2 or high risk myelodysplastic syndrome, acute myeloid leukemia with 20-30% blasts and multi-lineage dysplasia, or chronic myelomonocytic

Femme et Homme

| Pays :
| Organes :
| Spécialités :

Extrait

Primary Objectives for the Phase 1b (Safety Lead-In) •To assess the safety and tolerability of PF 04449913 when administered in combination with azacitidine in patients with previously untreated Intermediate-2 or High-Risk MDS, AML with 20%-30% blasts and multi-lineage dysplasia or CMML. Primary Objectives for the Randomized Phase 2 Component •To demonstrate superior response rate (RR) of azacitidine and PF-04449913 versus azacitidine and placebo in the treatment of patients with previously untreated Intermediate-2 or High-Risk MDS, AML with 20-30% blasts and multi-lineage dysplasia and CMML.

Critère d'inclusion

Intermediate-2, High-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia with 20-30% Blasts and Multi-Lineage Dysplasia, or Chronic Myelomonocytic Leukemia

Liens

ictrp
euctr

Kusajili – Centralise les essais cliniques mondiaux

Study to test the safety and efficacy of PF-04449913 with azacitidine versus placebo with azacitidine in patients with Intermediate-2 or high risk myelodysplastic syndrome, acute myeloid leukemia with...